RxDoctor Payments Data

Veronica Moino, DO

Internal Medicine · Columbia, SCNPI 1518584465

Payments from drug & device makers

$1,530in general payments, 2019–2025

Across 84 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$347
  • AstraZeneca$220
  • Novo Nordisk$176
  • Lilly USA, LLC$143
  • GSK$110
  • Boehringer Ingelheim$81
  • plus $453 from 19 others

What the payments were for

  • Food & beverage$1,530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,530 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$128,399
Medicare patients
420
Services billed
1,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$69,577
JardianceEmpagliflozin54$53,540
OzempicSemaglutide31$53,183
FarxigaDapagliflozin Propanediol28$37,210
EliquisApixaban21$24,994
JanuviaSitagliptin Phosphate26$23,654
MyrbetriqMirabegron22$16,144
XareltoRivaroxaban13$15,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,009
Spiriva RespimatTiotropium Bromide16$11,643
SymbicortBudesonide/Formoterol Fumarate12$2,598
Rosuvastatin Calcium163$1,941
Levothyroxine Sodium144$1,891
Atorvastatin Calcium191$1,745
Olmesartan Medoxomil70$1,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$143$69,57759 claims
Boehringer IngelheimJardiance, Spiriva Respimat$81$65,18470 claims
Novo NordiskOzempic$176$53,18331 claims
AstraZenecaFarxiga, Symbicort$220$39,80840 claims
PfizerEliquis$28$24,99421 claims
Astellas Pharma US IncMyrbetriq$28$16,14422 claims
GSKTrelegy Ellipta$110$15,00922 claims
AbbVieSynthroid$347$1,17221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →